About Us | Contact

Lucky Flores Investigator

Adult Medicine NPI1225007669
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$83,120.43
from 27 payments in the last 6 years

Total Cash or Cash Equivalent

$69,827.00
from 8 payments in the last 6 years

Total In-kind Items & Services

$13,293.43
from 19 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
06/21/2021 Research Cash or cash equivalent $2643.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 2 MULTICENTER RANDOMIZED PARALLEL-ARM PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH ACTIVE CROHNS DISEASE (SERENITY)
Clinical Trials Gov ID NCT02891226
Payment Record ID 819445179
01/12/2021 Research Cash or cash equivalent $5537.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO- AND ACTIVE- CONTROLLED TREAT-THROUGH STUDY OF MIRIKIZUMAB AND VEDOLIZUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Clinical Trials Gov ID NCT04469062
Payment Record ID 819445177
03/26/2020 Research In-kind items and services $517.70 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3
Clinical Trials Gov ID NCT03519945
Payment Record ID 728722207
11/19/2020 Research In-kind items and services $1098.73 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
Clinical Trials Gov ID NCT03926130
Payment Record ID 728721775
01/18/2019 General (Non-Research) In-kind items and services Food and Beverage $249.47 Details
Payment from PFIZER INC.
Payment Record ID 671928673
01/08/2019 Research In-kind items and services $121.78 Details
Payment from Allergan Inc.
Paymment Research Study A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Payment Record ID 670006517
01/08/2019 Research In-kind items and services $264.38 Details
Payment from Allergan Inc.
Paymment Research Study A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Payment Record ID 670006513
01/08/2019 Research In-kind items and services $151.15 Details
Payment from Allergan Inc.
Paymment Research Study A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Payment Record ID 670006505
08/27/2019 Research In-kind items and services $303.28 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3
Clinical Trials Gov ID NCT03519945
Payment Record ID 654283327
01/28/2019 Research In-kind items and services $2081.43 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1)
Clinical Trials Gov ID NCT03518086
Payment Record ID 654283125
03/14/2018 General (Non-Research) Cash or cash equivalent Consulting Fee $547.00 Details
Payment from SANOFI-AVENTIS U.S. LLC
Payment Record ID 602968787
09/14/2018 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $400.00 Details
Payment from SANOFI-AVENTIS U.S. LLC
Payment Record ID 602942503
12/03/2018 General (Non-Research) In-kind items and services Food and Beverage $20.20 Details
Payment from Genentech, Inc.
Payment Record ID 602541699
07/26/2018 Research In-kind items and services $1248.40 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1)
Clinical Trials Gov ID NCT03518086
Payment Record ID 585603711
03/27/2018 Research In-kind items and services $2906.15 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 2 MULTICENTER RANDOMIZED PARALLEL-ARM PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH ACTIVE CROHNS DISEASE (SERENITY)
Clinical Trials Gov ID NCT02891226
Payment Record ID 585603709
01/16/2017 Research In-kind items and services $3167.27 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 2 MULTICENTER RANDOMIZED PARALLEL-ARM PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH ACTIVE CROHNS DISEASE (SERENITY)
Clinical Trials Gov ID NCT02891226
Payment Record ID 457097779
05/04/2016 General (Non-Research) In-kind items and services Education $25.00 Details
Payment from Teva Pharmaceuticals USA, Inc.
Payment Record ID 414304759
08/13/2016 General (Non-Research) In-kind items and services Travel and Lodging $341.10 Details
Payment from Sandoz Inc.
Payment Record ID 387596294
08/13/2016 General (Non-Research) In-kind items and services Food and Beverage $50.00 Details
Payment from Sandoz Inc.
Payment Record ID 387596264
08/13/2016 General (Non-Research) In-kind items and services Food and Beverage $32.00 Details
Payment from Sandoz Inc.
Payment Record ID 387596232
08/13/2016 General (Non-Research) In-kind items and services Food and Beverage $25.00 Details
Payment from Sandoz Inc.
Payment Record ID 387596204
08/13/2016 General (Non-Research) In-kind items and services Food and Beverage $24.99 Details
Payment from Sandoz Inc.
Payment Record ID 387596172
11/22/2016 Research In-kind items and services $665.40 Details
Payment from Eli Lilly and Company
Paymment Research Study A PHASE 2 MULTICENTER RANDOMIZED PARALLEL-ARM PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH ACTIVE CROHNS DISEASE (SERENITY)
Clinical Trials Gov ID NCT02891226
Payment Record ID 372521596
12/23/2016 Research Cash or cash equivalent $34800.00 Details
Payment from Taro Pharmaceuticals USA, Inc.
Paymment Research Study TARO Research Projects
Payment Record ID 361373119
11/30/2016 Research Cash or cash equivalent $6200.00 Details
Payment from Taro Pharmaceuticals USA, Inc.
Paymment Research Study TARO Research Projects
Payment Record ID 361373102
10/28/2016 Research Cash or cash equivalent $9000.00 Details
Payment from Taro Pharmaceuticals USA, Inc.
Paymment Research Study TARO Research Projects
Payment Record ID 361373083
11/30/2016 Research Cash or cash equivalent $10700.00 Details
Payment from Taro Pharmaceuticals USA, Inc.
Paymment Research Study TARO Research Projects
Payment Record ID 361373068
;